Liminatus Pharma, Inc. Class A Common Stock
LIMN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $36,030 | $40,143 | $172,486 | $172,845 |
| - Cash | $805 | $434 | $5,048 | $336 |
| + Debt | $5,122 | $16,050 | $16,500 | $90 |
| Enterprise Value | $40,348 | $55,759 | $183,938 | $172,599 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$2,747 | -$1,089 | -$2,709 | $4,370 |
| % Margin | – | – | – | – |
| Net Income | -$2,904 | -$1,226 | -$2,928 | $4,370 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.4 | -0.15 | -0.082 | 0.13 |
| % Growth | -166.7% | -82.3% | -163.3% | – |
| Operating Cash Flow | -$3,106 | -$3,345 | -$869 | -$1,216 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$3,106 | -$3,345 | -$869 | -$1,216 |